Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Prostatic Neoplasms 4Breast Neoplasms 2Wilms Tumor 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Pancreatic Intraductal Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Ganglioneuroblastoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Carboplatin 195Cisplatin 117Paclitaxel 107Pemetrexed 106Docetaxel 96Gemcitabine 89Radiotherapy 83Erlotinib Hydrochloride 58Bevacizumab 55Etoposide 49durvalumab 39pembrolizumab 38Nivolumab 31Specimen Handling 30Magnetic Resonance Spectroscopy 30Irinotecan 27Radiosurgery 26osimertinib 24Gefitinib 24Drug Therapy 23Vinorelbine 22atezolizumab 20Topotecan 20Radiation 16Cetuximab 16Taxes 15Surgical Procedures, Operative 14Neoadjuvant Therapy 13Filgrastim 13Chemotherapy, Adjuvant 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lung Neoplasms × Congresses as Topic × Clear all
NCT04989283 2023-09-26

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡